RRM1与上皮性卵巢癌化疗耐药关系的探讨
刘宁;王黎明;
摘要(Abstract)：
<正>卵巢癌是死亡率最高的女性生殖道恶性肿瘤患者对化疗药物易产生耐药是治疗失败的主要原因之一。研究卵巢癌耐药机理,探索可以指导临床用药的客观试验指标十分必要。核糖核苷酸还原酶亚单位(ribonucleotide reductase subunit M1,RRM1)是最近被广泛关注的一个肿瘤耐药基因,已证实其表
关键词(KeyWords)： 核糖核苷酸还原酶亚单位;上皮性卵巢癌;化疗耐药
基金项目(Foundation):
作者(Authors): 刘宁;王黎明;
DOI: 10.13283/j.cnki.xdfckjz.2011.07.023
参考文献(References)：
- [1]王慧敏,冯久贤,张雪艳,等.ERCC1/RRM1和P53表达与Ⅰ-Ⅱ期肺癌术后预后相关性分析[J].中国肺癌杂志,2009,12(5):137-139
- [2]沈铿.复发性卵巢癌的诊断和治疗策略[J].现代妇产科进展,2005,14(3):177-180
- [3]金平,秦晓黎,赵全明,等.卵巢上皮性癌顺铂耐药细胞的化疗药物敏感性及P型铜转运三磷酸腺苷酶和P糖蛋白的表达[J].中华妇产科杂志,2009,44(10):793-795
- [4]Herrick J,Sciavl B.Ribonucleotide reductase and the reg-ulation of DNA replication:an old story and ancient herit-age[J].Mol Microbiol,2007,63(1):22-34
- [5]Rosell R,Cobo M,Isla D,et al.Pharmacogenomics andgemcitabine[J].Annals of Oncology,2006,17:13-16
- [6]Davidson JD,Ma L,Flagella M,et al.An increase in theexpression of ribonucleotide reductase large subunit 1 isassociated with gemcitabine resistence in non-small celllung cancer cell lines[J].Cancer Res,2004,64(11):3761-3766
- [7]Nakahira S,Nakamori S,Tsujie M,et al.Involvement ofribonucleotide reductase M1 subunit overexpression ingemcitabine resistance of human pancreatic cancer[J].Int J Cancer,2007,120(6):1355-1363
- [8]Smid K,Bergman AM,Eijk PP,et al.Micro-array analysisof resistance for gemcitabine results in increased expres-sion of ribonucleotide reductase subunits[J].NucleosidesNucleotides Nucleic Acids,2006,25(9-11):1001-1007
- [9]Bergman AM,Eijk PP,Ruiz van Haperen VW,et al.In vi-vo induction of resistance to gemcitabine results in in-creased expression of ribonucleotide reductase subunit M1as the major determinant[J].Cancer Res,2005,65(20):9510-9516
- [10]Van de Wiel MA,Costa JL,Smid K,et al.Expressionmicroarray analysis and oligo array comparative genomichybridization of acquired gemcitabine resistance inmouse colon reveals selection for chromosomaI aberra-tions[J].Cancer Res,2005,65(22):10208-10213
- [11]任婧婧,王黎明,卢飞飞,等.RRM1表达与宫颈鳞癌新辅助化疗敏感性的关系[J].现代妇产科进展,2011,20(5):121-123
- [12]Lord RVN,Braberder J,Gandera D,et al.Low ERCC1expression correlates with prolonged survival after cispla-tin plus gremcitabine chemotherapy in non-small celllung cancer[J].Clin Cancer Res,2002,8:2286-2291
- [13]Rosell R.Predictive molecular markers in non-small celllung cancer[J].Curt Opin Oncol,2001,13:101-106